DelSiTech, Innovare to develop long acting HIV therapy
Finland-based DelSiTech and Mexican pharma company Innovare R&D have signed a world-wide, exclusive license agreement for the use of the former’s Silica Matrix drug delivery platform in the development and commercialization of a long acting HIV therapy.